Over the past decade, the variety and therapeutic potential of cancer medicines have escalated significantly. New classes of treatment are prolonging the lives of many people with advanced disease.
Critics suggest that rapid approval of relatively untested medicines engenders false hope, puts people at unnecessary risk from toxicity and jeopardizes the stepwise accretion of medical knowledge that RCTs would provide.
[
add
]
[
|
|
...
]